Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats

References

• Bedada SK, Sudhakar YA, Neerati P. (2014). Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: involvement of P-glycoprotein inhibition. J Bioequivalence Bioavailab 6:158–63.
   Google Scholar
• Bedada SK, Yellu NR, Neerati P. (2016). Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: involvement of P-glycoprotein inhibition. Pharmacol Rep 68:338–43.
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–71.
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. (2009). Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 26:883–92.
   PubMed Web of Science ®Google Scholar
• Duan P, You G. (2009). Novobiocin is a potent inhibitor for human organic anion transporters. Drug Metab Dispos 37:1203–10.
   PubMed Web of Science ®Google Scholar
• Gertz M, Harrison A, Houston JB, et al. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147–58.
   PubMed Web of Science ®Google Scholar
• Gotanda K, Tokumoto T, Hirota T, et al. (2015). Sulfasalazine disposition in a subject with 376C > T (nonsense mutation) and 421C > A variants in the ABCG2 gene. Br J Clin Pharmacol 80:1236–7.
   PubMed Web of Science ®Google Scholar
• Kadono K, Koakutsu A, Naritomi Y, et al. (2014). Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method. Xenobiotica 44:511–21.
   PubMed Web of Science ®Google Scholar
• Kamath AV, Yao M, Zhang Y, et al. (2005). Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233–9.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, et al. (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203.
   PubMed Web of Science ®Google Scholar
• Kunimatsu S, Mizuno T, Fukudo M, et al. (2013). Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats. Drug Metab Dispos 41:1592–7.
   PubMed Web of Science ®Google Scholar
• Lau YY, Chen YH, Liu TT, et al. (2004). Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. Drug Metab Dispos 32:937–42.
   PubMed Web of Science ®Google Scholar
• Lee HK, Hu M, Lui SSh, et al. (2013). Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 14:1283–94.
   PubMed Web of Science ®Google Scholar
• Li R, Barton HA. (2018). Explaining ethnic variability of transporter substrate pharmacokinetics in healthy Asian and Caucasian subjects with allele frequencies of OATP1B1 and BCRP: a mechanistic modeling analysis. Clin Pharmacokinet 57:491–503.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Konno Y, Hashimoto T, et al. (2013). In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats. Drug Metab Dispos 41:1514–21.
   PubMed Web of Science ®Google Scholar
• Mitschke D, Reichel A, Fricker G, et al. (2008). Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 36:1039–45.
   PubMed Web of Science ®Google Scholar
• Pade V, Stavchansky S. (1998). Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci 87:1604–7.
   PubMed Web of Science ®Google Scholar
• Peng Y, Yadava P, Heikkinen AT, et al. (2014). Applications of a 7-day Caco-2 cell model in drug discovery and development. Eur J Pharm Sci 56:120–30.
   PubMed Web of Science ®Google Scholar
• Soko ND, Chimusa E, Masimirembwa C, et al. (2019). An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T > C and ABCG2 c.421A > C. Pharmacogenomics J 19:240–8.
   PubMed Web of Science ®Google Scholar
• Su Y, Hu P, Lee SH, et al. (2007). Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharm Sci 10:519–36.
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Sugiyama Y. (2012). Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values. Pharm Res 29:651–68.
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Delahaye S, et al. (2004). Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 308:1121–9.
   PubMed Web of Science ®Google Scholar
• Wan Z, Wang G, Li T, et al. (2015). Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G > A and 421C > A homozygote or compound heterozygote. J Pharmacol Exp Ther 354:310–5.
   PubMed Web of Science ®Google Scholar
• Wang X, Morris ME. (2007). Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268–74.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kosugi Y, Hirabayashi H, et al. (2018). Impact of P-Glycoprotein on intestinal absorption of an Inhibitor of apoptosis protein antagonist in rats: mechanisms of nonlinear pharmacokinetics and food effects. Pharm Res 35:190.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yu BN, He YJ, et al. (2006). Role of BCRP 421C > A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Ruan ZR, Yuan H, et al. (2013). ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Pharmazie 68:129–34.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang F, Chen C, et al. (2017). Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica 47:267–75.
   PubMed Web of Science ®Google Scholar